Skip to main content

Notice on the Supplement to the Agenda of the Extraordinary General Meeting of Shareholders of LITGRID AB

LITGRID AB (legal entity code 302564383), registered office address at 8 Karlo Gustavo Emilio Manerheimo St., LT-05131 Vilnius (hereinafter – the Company), has received a notice from its majority shareholder, UAB “EPSO-G”, holding 97.5 per cent of the shares and votes, proposing to supplement the agenda of the Extraordinary General Meeting of Shareholders to be held on 28 September 2026 with the following item and draft resolution:Regarding the approval of the new version of the Articles of Association of LITGRID ABProposed draft decision: “1.1. To approve the new version of the Articles of Association of LITGRID AB (attached). 1.2. To authorise the Chief Executive Officer of LITGRID AB (with the right to sub-delegate such authority), in accordance with the procedure established by applicable laws and regulations, to sign the amended...

Continue reading

Micropolis Robotics Brings UAE-Developed Physical AI to the Annual Investment Meeting 2026

Autonomous robots showcased alongside Dubai Police before government delegations and investorsMicropolis Showcases Physical AI at AIM Congress 2026Micropolis Robotics showcases its autonomous robots alongside Dubai Police at AIM Congress 2026 in DubaiDUBAI, United Arab Emirates, Sept. 07, 2026 (GLOBE NEWSWIRE) — Micropolis Robotics (NYSE American: MCRP), a leading UAE-based developer of autonomous mobile robots and AI-enabled systems, is participating in the Annual Investment Meeting (AIM Congress 2026) in Dubai, using the global platform to advance its growth and present its locally developed autonomous technologies to international decision-makers. During the three-day event at Dubai World Trade Centre, Micropolis is showcasing its autonomous robotic platforms alongside Dubai Police before an audience of senior government...

Continue reading

Schouw & Co. share buy-back programme, week 36 2026

On 2 January 2026, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 59 of 18 December 2025. Under the programme, Schouw & Co. will acquire shares for up to DKK 240 million during the period 2 January to 31 December 2026. As outlined in Company Announcement no. 48 of 14 August 2026, the programme was extended with up to DKK 170 million, increasing the total amount of which Schouw & Co. will acquire shares to up to DKK 410 million. The buy-back will be structured in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (“Safe Harbour” rules).Trading day No. of shares Average price Amount DKK    Accumulated until 28 August 2026 325,483 666.30 216,869,061    Monday,...

Continue reading

A notice of the convening of the Extraordinary General Meeting of Shareholders of AB Amber Grid

New energy group EPSO-G (legal entity code 302826889, registered office address: Laisvės pr. 10, Vilnius, Lithuania) At the initiative of and subject to the Decision of 07 September 2026 of the Board of AB Amber Grid (company code 303090867), registered office address: Laisvės ave. 10, LT-04215 Vilnius, Lithuania (the “Company”), the Ordinary General Meeting of Shareholders (the “Meeting”) of the Company is convened. By its decision, the Board also approved the agenda of the Meeting and the draft of the decision. The Meeting is convened at Laisvės ave. 10, LT-04215 Vilnius, Lithuania, Laisvės Energijos hall, on 29 October 2026 (on Thursday), at 10:00 a.m. (Lithuanian time).The beginning of the shareholders’ registration: on 29 October 2026, at 09:30 a.m. (Lithuanian time). To ensure an effective registration process, the shareholders are...

Continue reading

A notice of the convening of the Extraordinary General Meeting of Shareholders of AB Amber Grid

At the initiative of and subject to the Decision of 07 September 2026 of the Board of AB Amber Grid (company code 303090867), registered office address: Laisvės ave. 10, LT-04215 Vilnius, Lithuania (the “Company”), the Ordinary General Meeting of Shareholders (the “Meeting”) of the Company is convened. By its decision, the Board also approved the agenda of the Meeting and the draft of the decision. The Meeting is convened at Laisvės ave. 10, LT-04215 Vilnius, Lithuania, Laisvės Energijos hall, on 29 October 2026 (on Thursday), at 10:00 a.m. (Lithuanian time). The beginning of the shareholders’ registration: on 29 October 2026, at 09:30 a.m. (Lithuanian time). To ensure an effective registration process, the shareholders are called upon to inform in advance about their intention to attend the Meeting by email info@ambergrid.lt. The end...

Continue reading

Disclosure of trading in own shares from August 31, 2026 to September 4, 2026

Head Office : 39, Esplanade du Général de Gaulle 92800 Puteaux La Défense, France  Tel : + 33 (0) 1 59 23 65 00 – www.nexans.com  a French Société Anonyme with a share capital of € 43,746,793 – R.C.S. Nanterre 393 525 852 – Id VAT FR 74 393 525 852                           Disclosure of trading in own shares                    From August 31, 2026 to September 4, 2026                  Issuer : Nexans                      Category : treasury shares                                               Pursuant to applicable law on share buybacks, Nexans declares the following purchases of its own shares from August 31, 2026 to September 4, 2026                           The trades have been executed within the framework of the description of the buyback program published on April 2nd, 2026, on the Company’s...

Continue reading

Form-8.3 ADVANCED MEDICAL SOLUTIONS GROUP PLC – 04 09 2026 – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree ADVANCED MEDICAL SOLUTIONS GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date...

Continue reading

Festi hf.: Transactions in relation to a share repurchase programme – week 36

In week 36 2026, Festi purchased in total 185,213 own shares for total amount of 56,487,039 ISK as follows:Week Date Time Purchased shares Share price Purchase price  36 31.8.2026 11:27:21 75.000 304,5 22.837.50036 2.9.2026 12:44:08 147 303,0 44.54136 2.9.2026 13:10:09 50.000 304,5 15.225.00036 2.9.2026 13:26:10 66 303,0 19.99836 4.9.2026 13:16:34 39.706 306,0 12.150.03636 4.9.2026 13:16:34 10.000 306,0 3.060.00036 4.9.2026 14:31:45 10.294 306,0 3.149.964                 185.213   56.487.039                       The execution of the buyback program is in accordance with the Act on Public Limited Companies No 2/1995, Article 5 of the Regulation of the European Parliament and of the Council No. 596/2014, on market abuse, the Commission Delegated Regulation No. 2016/1052 and the Act on Actions against...

Continue reading

Teva Announces Launch of Offering of Senior Notes

TEL AVIV, Israel, Sept. 07, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today its intention to issue senior notes through its special purpose finance subsidiaries. Teva Pharmaceutical Finance Netherlands II B.V. (“Teva Finance II”) intends to offer EUR-denominated Senior Notes (the “Euro Notes”) and Teva Pharmaceutical Finance Netherlands III B.V. (“Teva Finance III”) and Teva Pharmaceutical Finance Netherlands IV B.V. (“Teva Finance IV” and, together with Teva Finance II and Teva Finance III, the “Issuers”) intend to offer USD-denominated Senior Notes (the “USD Notes” and, together with the Euro Notes, the “Notes”). The offering of Notes is subject to, among other things, market conditions. Teva expects to use the net proceeds from the offering, together with cash on hand,...

Continue reading

AL Sydbank A/S share buyback programme: transactions in week 36

        Company Announcement No 50/2026Peberlyk 46200 AabenraaDenmark Tel +45 74 37 37 37 AL Sydbank A/SCVR No DK 12626509, Aabenraaal-sydbank.com7 September 2026  Dear Sirs AL Sydbank A/S share buyback programme: transactions in week 36On 25 February 2026 AL Sydbank A/S announced a share buyback programme of DKK 1,100m. The share buyback programme commenced on 2 March 2026 and will be completed by 31 January 2027. The purpose of the share buyback programme is to reduce the share capital of AL Sydbank A/S and the programme is executed in compliance with the provisions of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 and Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016, collectively referred to as the Safe Harbour rules. The following transactions have been made under...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.